ALM-201

N/A

Report date: 2022/11/25 18:10:02
NME

Base Information

Drug NameALM-201
Drug Alias NameFKBPL-derived anticancer peptidesFKBP-LALM-201FKBPLFKBP-L
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiogenesis inhibitorsTubulin inhibitorsCD44 antigen modulators
TargetsTubulinCD44 antigen
Therapy Area/IndicationsSolid tumoursEye DiseasesOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlmac Discovery Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlmac Discovery Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursEye DiseasesOvarian Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A